Capricor Therapeutics, Inc.

NASDAQ:CAPR

Biotechnology

Healthcare
$8.41 -0.50%

-$0.14 today

Market cap
$487.04M
Beta
0.37
P/E (TTM)
-13.9
EPS (TTM)
-$2.00
52W Low $4.30High $40.37

Volume 4.62M

Average 1.08M

Returns on capital

Capricor Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-34.4%

avg 70.7%

ROIC

-33.4%

avg -87.7%

ROA

-29.5%

avg -57.8%

Analysis

ROA is currently the strongest return metric at -29.5% versus its period average of -57.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Anthony J. Bergmann

Chief Financial Officer & Corporate TreasurerUSD 584.75K40——

Linda Marbán

Co-Founder, President, Chief Executive Officer & DirectorUSD 580.65K637.50K0.02%

Karen G. Krasney

Executive Vice President, General Counsel & SecretaryUSD 500.72K73——

Frank Isaac Litvack FACC

Executive Chairman of the BoardUSD 120K70——

Kristi A. H. Elliott

Chief Operating & Science Officer————

Mark Awadalla

Chief Development Officer————

Michael Maurer

Chief Commercial Officer————

Minghao Sun

Senior Vice President of Quality Control, Research & Product Development————

Nathaniel Hogan

Director of Biostatistics of Capricor Therapeutics————

Micheal Binks

Chief Medical Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 5, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

11

$8.34M

Net Transaction Value

−$8.34M

Net selling

Most Active

Bergmann Anthony

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jun 25, 26

Bergmann Anthony

Direct

Sell$732.2K
Jun 25, 26

Krasney Karen

Direct

Sell$732.2K
Jun 24, 26

Bergmann Anthony

Direct

Sell$12K
Jun 24, 26

Krasney Karen

Direct

Sell$12K
May 1, 26

Krasney Karen

Direct

Sell$792.5K
May 1, 26

Bergmann Anthony

Direct

Sell$792.5K
Apr 2, 26

Sabar Karimah Es

Direct

Sell$240.9K
Apr 1, 26

Sabar Karimah Es

Direct

Sell$1.7M
Mar 31, 26

Sabar Karimah Es

Direct

Sell$1.8M
Mar 31, 26

Krasney Karen

Direct

Sell$752.9K

1–10 of 11

Summary

Insiders reported 0 buys worth $0.00 and 11 sells worth $8.34M over the last 12 months. That adds up to net selling of $8.34M. Bergmann Anthony was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Capricor Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CAPR's management, answered from reported figures.

Who manages CAPR?

Capricor Therapeutics, Inc. (CAPR) lists 10 active executives. The top listed executive is Frank Isaac Litvack FACC, Executive Chairman of the Board.

Are CAPR insiders buying or selling?

Recent insider activity shows net selling of $916.36M.